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Abstract
Background: Severe asthma in horses, known as severe equine asthma (SEA), is a
prevalent, performance-limiting disease associated with increased allergen-specific
immunoglobulin E (IgE) against a range of environmental aeroallergens.
Objective: To develop a protein microarray platform to profile IgE against a range of
proven and novel environmental proteins in SEA-affected horses.
Animals: Six SEA-affected and 6 clinically healthy Warmblood performance horses.
Methods: Developed a protein microarray (n = 384) using protein extracts and puri-
fied proteins from a large number of families including pollen, bacteria, fungi, and
arthropods associated with the horses, environment. Conditions were optimized and
assessed for printing, incubation, immunolabeling, biological fluid source, concentra-
tion techniques, reproducibility, and specificity.
Results: This method identified a number of novel allergens, while also identifying an asso-
ciation between SEA and pollen sensitization. Immunolabeling methods confirmed the
accuracy of a commercially availablemouse anti-horse IgE 3H10 source (R2 = 0.91). Biologi-
cal fluid source evaluation indicated that sera and bronchoalveolar lavage fluid (BALF)
yielded the same specific IgE profile (average R2 = 0.75). Amicon centrifugal filters were
found to be themost efficient technique for concentrating BALF for IgE analysis at 40-fold.
Overnight incubation maintained the same sensitization profile while increasing sensitivity.
Reproducibility was demonstrated (R2 = 0.97), as was specificity using protein inhibition
assays. Arthropods, fungi, and pollens showed the greatest discrimination for SEA.
Conclusions and Clinical Importance: We have established that protein microarrays
can be used for large-scale IgE mapping of allergens associated with the environment
of horses. This technology provides a sound platform for specific diagnosis, manage-
ment, and treatment of SEA.
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1 | INTRODUCTION
Severe asthma in horses, known as severe equine asthma (SEA), is a
performance-limiting, allergic response to inhaled allergens in genetically
predisposed horses that affects approximately 14% of the equine popula-
tion in the United Kingdom.1-3 Allergen exposure in affected horses results
in small airway inflammation, mucus hypersecretion, and
bronchoconstriction, altering pulmonary resistance, dynamic compliance,
and pleural pressure.4-6 The predominant source of these aeroallergens is
the organic dust portion of forage and bedding, which contains fungi, bacte-
ria, pollen, and arthropods.7-11 Removal from the aeroallergen-rich stabling
environment results in some degree of remission,12 but owner compliance
is limited because of seasonality, competition schedule, health issues, and
nutritional demands. Treatments with corticosteroids and bronchodilators
provide short-term relief, but such therapeutic approaches have been asso-
ciated with undesirable adverse effects, and their use is prohibited under
Fédération Équestre Internationale and Jockey Club rules.13,14 Allergen avoid-
ance is the cornerstone of prevention and effective treatment, but the effi-
cacy of the latter approach relies on identification of causal allergens.15
Currently, the main obstacles to diagnostic and therapeutic developments
include major limitations in the number of allergens screened to establish
causal agents and lack of a clinically applicable in vitro test.
The pathogenesis of this condition remains unclear, but several stud-
ies have implicated immunoglobulin E (IgE) by in vitro histamine release
assays,16-18 natural hay and straw challenges,19 intradermal testing,20 and
specific IgE (sIgE) analysis of bronchoalveolar lavage fluid (BALF) and
sera.21,22 The sIgE assays suggest that Aspergillus fumigatus, Alternaria
alternate, rAsp f 8, Tyrophagus putrescentiae, Saccharopolyspora rectivirgula,
Asp f 1/a, Aspergillus terreus, Eurotium amstelodami, Geotrichum candidum,
andWallemia sebi are implicated in the etiology of SEA.8,21,23-25 Although
many recombinant proteins are available,26 advances in causal allergen
identification have been limited because of the practicality of testing with
classical methods, such as ELISA, which are time-consuming, expensive,
and require large quantities of samples and reagents.27
In recent years, protein microarrays have been gaining popularity in
allergy diagnostic testing because of their ability to assess the interac-
tion of thousands of proteins with specific immunoglobulin isotypes
using techniques such as fluorescence on a miniaturized scale, a tech-
nique known as microarray profiling.28 This technique circumvents the
aforementioned limitations associated with techniques such as ELISA,
enabling multiallergen testing to assess complex sensitization profiles.
Furthermore, with specific allergens, these tests show similar sensitivity
to standard laboratory methods, including ELISA, UniCAP, radioallergo-
sorbent test (RAST), ImmunoCAP, and immunoblot testing.29-31 Previ-
ously published sensitivity and specificity values using protein
microarrays have indicated the high discriminatory power of the protein
extracts and pure recombinant Culicoides proteins associated with
insect bite hypersensitivity in the horse.22
Our aim was to develop a widespread allergen profiling technique
using microarray methods that would enable rapid and accurate IgE
profiling of SEA-affected horses. Furthermore, we wanted to analyze
the correlation between BALF and sera-specific IgE profiles, a crucial
consideration with respect to diagnostic sample requirements. Profil-
ing data allows for advances in diagnostic testing and treatment.
2 | MATERIALS AND METHODS
2.1 | BALF and sera samples
Clinical assessment including physical examination, pulmonary function
tests, and BALF cytology was used to define the inclusion and exclusion
criteria for the selection of 6 horses with SEA and 6 control horses.5
Bronchoalveolar lavage fluid was collected as previously described,32
filtered through a 100-mL syringe filter (Biocomma, Shenzhen, China),
and decanted into 10-mL aliquots in 15-mL centrifuge tubes with the
addition of Thermo Scientific Pierce Mini-Protease Inhibitor Tablets—
EDTA free (product # 13437766). The mixture was gently agitated and
incubated at 4C for 10 minutes before addition of 2.5 mL of glycerol
(Fisher Scientific, Leicestershire, United Kingdom) and stored at −80C
until analysis. To concentrate, BALF was thawed, maintained at 4C,
and filtered using a Sartorius Stedim 0.45-μm filter syringe (product #
17598). The BALF samples then were concentrated in an Amicon
Ultra-15 centrifugal filter (product # UFC905024) and used immedi-
ately. Blood was collected, and sera were prepared as previously
described,33 before storage at −80C until analysis, at which time sam-
ples were thawed at room temperature and placed on ice.
2.2 | Proteins, printing and hybridization
To maximize utility, the microarray was designed to be as comprehensive
as possible by including extracts and pure proteins from a wide range of
protein families derived predominantly from fungi, bacteria, pollen, and
arthropods. The extracts and pure proteins were obtained from commer-
cial suppliers, produced in house, and from donations. Because of the
limited commercial availability of some bacterial and fungal protein
extracts, it was necessary to produce them in house. Lyophilized purified
samples of the desired strain were purchased from Deutsche Sammlung
von Mikroorganismen und Zellkulturen (https://www.dsmz.de) and
grown in 150 mL of liquid media according to the supplier's recommen-
dation (250-mL Erlenmeyer flask). Once grown, the media were cen-
trifuged in 50-mL tubes at 4000g for 10 minutes, and the supernatant
was carefully removed before washing the individual pellets in 5 mL of
phosphate buffered saline (PBS). The tubes were centrifuged at 4000g
for 10 minutes, the supernatant was removed, and 1 mL of lysis buffer
solution was added to each tube (PBS, 0.5% TritonX-100 wt/vol and
Thermo Scientific EDTA free protease inhibitor mini-tablet). The
resuspended pellets were pooled into a single 50-mL centrifuge tube,
placed on ice, and sonicated using an MSE Soniprep 150 (15 seconds
sonication with 30-second cooling periods in between for 10 cycles).
Subsequently, the solution was filtered through a Nalgene 0.45-μm
syringe filter (product # 190-25-45), and the protein content quantified
using a Pierce Bicinchoninic Acid Protein Assay Kit (product # 23225).
The remaining solution underwent lyophilization, was resuspended in
MiliQ water with 10% glycerol (filtered through a 0.02 μm syringe filter),
and was normalized to 1 mg/mL protein and stored at −80C.
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Bronchoalveolar lavage concentration work initially was conducted
using slides described previously and consisting of extracts (n = 240) and
pure proteins (n = 120) from a range of protein families, including fungi,
pollens, and arthropods, to establish the optimal BALF concentration to
be utilized in subsequent development work.22 In house extracts not
present in the initial array setup were tested by printing normalized sam-
ples (1 mg/mL protein) onto 16-pad FAST slides (Whatman Schleicher &
Schuell, Dassel, Germany) using a QArraylite arrayer (Genetix, United
Kingdom). After sample selection, a new set of 384 proteins (see
Supporting Information Appendix) was printed in a professional setting
using a Marathon microarrayer (ArrayJet, Roslin, Scotland) printer as pre-
viously described22 with an approximate spot size of 200 μm diameter
and replicated with even spacing 2 times across each of the individual
16 pads into 2 identical blocks to final spot density of 12 288
spots/slide. For alignment and quality control, spots of Cy3, Cy5, and
PBS were printed onto each slide. Once printed, slides were blocked for
3 hours at 37C in 3% bovine serum albumin (BSA; wt/vol) in PBS inside
a Corning 5 slide holder (product # 40082) using a mini hybridization
oven (Appligene, USA), washed 3 times for 2 minutes in PBS containing
0.05% (wt/vol) Tween-20, followed by five 1-minute washes with MiliQ
water, and dried by centrifugation (MSE Mistral 3000i, Sanyo, United
Kingdom) at 1000g for 10 minutes at room temperature.
Slides were fitted with Proplate slide modules (Grace Bio-Labs, prod-
uct # 204862) and washed 3 times (60-second dwell time) with PBS with
Tween 20 (PBST; Tween at 0.2%). Samples (BALF/sera) were diluted in a
ratio of 1:2 with 4% BSA in PBST (Tween at 0.4% wt/vol) containing
Thermo Scientific Pierce Mini-Protease Inhibitor Tablets—EDTA free
(product # 13437766; 1 tablet in 5 mL), which previously had been pas-
sed through a Whatman 13-mm, 0.45-μm filter syringe (product #
6784-1304). One hundred microliters of the prepared sample was added
to each well, excluding well 4, which was used as control and filled with
100 μL of the dilution solution (1:2) in PBS. The Proplate was fitted with
an adhesive seal strip and incubated for 16 hours at 4C on the Stuart
mini see-saw rocker (SSM4) at 13 oscillations/minute. Slides were
washed 3 times with PBST (Tween at 0.05%) using the BioTek plate
washer and incubated for 2 hours at 37C in a ThermoHybaid (HyPro
20) at vibration setting 3 with 100 μL per well of mouse anti-horse IgE
(BioRad, product # MCA5982GA) in a ratio of 1:400 in 1% BSA in PBST
(Tween at 0.2% w/v), washed 3 more times with PBST (Tween at 0.05%)
and incubated for 1 hour at 37C in the ThermoHybaid with 100 μL per
well of DyLight 649 conjugated anti-mouse IgG1 (Rockland, product #
610-443-040) in a ratio of 1:400 in 1% BSA in PBST (Tween at 0.2%
wt/vol). The slide then was washed 3 times in PBST (Tween at 0.05%)
followed by 3 washes with Milli-Q water, and dried by centrifugation at
300×g for 10 minutes (Mistral 3000i, rotor 43124-708).
2.3 | Data analysis
Processed slides were scanned in a GenePix 4000B (Molecular devices,
USA) with the photomultiplier tube settings at 440 and 310 at 635 and
532 nm, respectively, and saved as TIF files. Images were processed in
GenePix Pro software v6.0.1.27 (Axon Instruments) and saved as
comma-delimited text files. Fluorescence values were calculated for each
spot by subtracting local background from the median fluorescence value
of the spot. One pad per slide contained all reagents with addition of PBS
instead of serum for control purposes; these results were deducted from
samples on the same slide to account for any protein autofluorescence
and nonspecific binding. Further analysis and data presentation were car-
ried out using Microsoft Excel. Average fluorescence values for each pro-
tein were compared between SEA and control groups using a
conventional Z-test in Excel (Microsoft, USA). The Benjamini-Hochberg
method was used to account for false discovery at a rate of 0.05.
Benjamini-Hochberg corrected values were considered significant at
P < .05. Linear regression (coefficient of determination) of IgE fluores-
cence values for all proteins (n = 384) was used to establish the relation-
ship between BALF and sera, reproducibility of results, and various
mouse anti-horse IgE sources. Bronchoalveolar lavage fluid concentration
techniques and concentrations were tested by 1-way analysis of variance.
Tukey's honestly significant difference test for multiple comparisons was
performed if significant differences were found (P < .05).
3 | RESULTS
3.1 | Optimizing sera incubation conditions
3.1.1 | BALF concentration techniques
Bronchoalveolar lavage fluid concentrations employing Amicon and
PD10/lyophilizing methods were compared using a BALF pool from
6 horses (n = 3 SEA and 3 control). Total IgE for each protein group
was used to compare concentration methods (Figure 1A) and indi-
cated no significant difference (P > .05) between concentration tech-
niques. The Amicon concentration method was used to evaluate
optimal BALF concentration by total IgE fluorescence for each protein
group, indicating that a plateau was reached at 40-fold concentration
(Figure 1B). Therefore, all subsequent BALF concentrations were car-
ried out by Amicon filtration to a 40-fold final concentration.
3.1.2 | Incubation time
Two conditions were tested for optimal sera incubation times using a
sera pool from 6 horses (n = 3 SEA and 3 control): 3 hours at 37C as
previously used for equine sera22 and overnight (16 hours) at 4C,
which previously has been shown to be more sensitive in studies per-
formed in humans.34 As shown in Figure 2, the IgE profile between the
2 incubation times was significantly correlated (R2 = 0.76). However,
when the serum was incubated for 16 hours at 4C, it was more sensi-
tive with 28.1% of proteins showing positive reactions, compared to
the 4 hours incubation, which showed 16.4% of proteins with positive
reactions (data not shown). Therefore, subsequent serological incuba-
tions were conducted overnight at 4C to increase sensitivity.
3.1.3 | Comparison of specific IgE in BALF and sera
Bronchoalveolar lavage samples concentrated by Amicon (40-fold)
were compared with sera from 6 horses (n = 3 SEA; n = 3 control),
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and correlation coefficients were calculated for each separate protein
group. Strong correlations were found between BALF and sera
(Table 1). Thus, all subsequent incubations were conducted with serum
because it is far easier to obtain, less invasive, more economical, and
stable to transport. Horse 5, a clinically healthy horse, showed poor
BALF/sera correlations across all protein groups, which was thought
to be a result of the horse recently changing to a different barn on the
same yard and, therefore, localized IgE production in the lung because
of environmental allergen correlated poorly with serological IgE.23,35
3.2 | Reproducibility
3.2.1 | Printing lot variation
The effect of printing lot on reproducibility of the protein microarray
was assessed using 2 microarray slides printed on the same day. Sera
from 3 SEA and 3 control horses was hybridized on the 2 slides simul-
taneously. Fluorescence results from replicate arrays were evaluated
using linear regression and indicated that fluorescence results from
the array were repeatable between printing lots (R2 = 0.97).
F IGURE 1 A, Bronchoalveolar lavage concentration optimization. Average BALF IgE fluorescence results for each protein group
demonstrating concentration efficacy for unconcentrated, and concentrated (10-fold) using either Amicon filter or PD10 columns/lyophilizing, A
1-way ANOVA for each protein group using a BALF pool from 6 horses (n = 3 SEA; n = 3 control) demonstrated there was no significant
difference (p > .05). Means that have no superscript in common are significantly different from each other. B, Average BALF pool horses (n = 3
SEA; n = 3 control) IgE fluorescence results for the main protein groups at various concentrations using Amicon filtration. Groupings included
arthropod, fungi, pollen and other; which largely consisted of food and environmental proteins. Significant differences of each protein group were
calculated individually by 1-way ANOVA with Tukey's HSD (* = p < .05). Means that have no superscript in common are significantly different
from each other
F IGURE 2 Comparison of incubation
methods. Linear regression of microarray
immunoglobulin E fluorescence results
(n = 384 proteins) of pooled sera (n = 3
severe equine asthma; n = 3 control)
incubated for 3 hours, 37C, and
16 hours, 4C, on a log scale
TABLE 1 Regression coefficients between total specific
immunoglobulin E fluorescence results between protein groups in
serum and bronchoalveolar lavage fluid (n = 6)
Pollen Arthropod Fungus Bacteria
Horse 1 0.63 0.82 0.71 0.74
Horse 2 0.79 0.96 0.73 0.91
Horse 3 0.65 0.92 0.54 0.88
Horse 4 0.91 0.99 0.56 0.72
Horse 5 0.44 0.58 0.33 0.89
Horse 6 0.87 0.85 0.59 0.98
4 WHITE ET AL.
3.2.2 | Comparison between monoclonal mouse
anti-horse 3H10 sources
Two mouse anti-horse IgE monoclonal antibodies (derived from
the 3H10 clone) were compared using linear regression of the fluores-
cence results using a sera pool from 6 horses (n = 3 SEA; n = 3 control),
which included the original 3H10 from a previous study36 and the
commercially available BioRad 3H10 (product # MCA5982GA).
As shown in Figure 3, the fluorescence results from the array had
a correlation coefficient of R2 = 0.91, indicating a significantly similar
IgE profiles.
3.3 | Specificity—protein inhibition assay
To test the IgE specificity of IgE-protein binding, a protein inhibition
assay was performed to assess cross-reactivity, in which pooled sera
were spiked with several proteins in serial dilution and the effect on
related and neighboring proteins evaluated. A protein inhibition assay
enables the confirmation of specificity of an antibody against the target
protein and usually is conducted using several proteins to confirm both
the antibody's specificity to the target protein and to assess potential
cross-reactivity.34 Two different protein inhibition groups were used,
each containing 2 different proteins. Group 1 consisted of Blattella
germanica (Bla g 1) and Rumex crispus (Rum cr), and group 2 consisted of
Penicillium notatum (Pen ch) and Acinetobacter gerneri (Aci g). Interest-
ingly, decreased fluorescence from proteins other than those targeted
also was observed, indicating either nonspecific inhibition or some simi-
larity among the allergenic components of the proteins. Group 1 showed
no nonspecific binding in the bacteria, arthropod, or fungi groups, but
cross-reactivity was seen among grass pollens, most notably Cynodon
dactylon, R crispus, Zea mays, and Anthoxanthum odoratum.
Group 2 demonstrated no nonspecific binding in the bacteria,
arthropod, and pollen groups, but cross-reactivity was seen among
Aspergillus niger, Aspergillus versicolor, Penicillium expansum, P notatum,
Aspergillus nidulans and A fumigatus (Figure 4).
3.4 | Allergen comparison
Whether or not the prototype array was able to identify novel aller-
gens associated with SEA was assessed using Z-tests with Benjamini-
Hochberg adjusted P-values among 6 SEA and 6 control sera samples.
The results shown in Table 2 confirmed the ability to conduct IgE
F IGURE 3 Comparison of secondary
antibodies. Linear regression comparing
protein microarray (n = 384)
immunoglobulin E (IgE) fluorescence
results on log scale from pooled sera
(n = 3 severe equine asthma; n = 3
control) using two mouse anti-horse IgE
3H10 clones; Wilson et al,36 and BioRad
(product # MCA5982GA)
F IGURE 4 Group 2 inhibition group
using pooled sera (n = 3 severe equine
asthma; n = 3 control). Group 2 proteins
(target protein: Penicilium notatum Pen ch)
deominstrated altered immunoglobulin E
fluorescence results between serial
dilutions for Aspergillus niger, Aspergillus
versicolor, Penicillium expansum, P
notatum, Aspergillus nidulans and
Aspergillus fumigatus, indicating cross-
reactivity/nonspecific binding
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profiling and identify potential SEA allergens using microarray
methods. As expected, it confirmed the presence of fungi and mite as
main reactants in the SEA population, while also identifying an associ-
ation with pollen which has not been implicated previously.
4 | DISCUSSION
We previously have determined the sensitivity and specificity of
microarrays in the diagnosis of insect bite hypersensitivity,22 con-
firming the high discriminatory power of complex extracts and pure
recombinant Culicoides proteins associated with the allergy. Based on
these principles, an array was constructed to enable multiallergen
testing and assess the complex sensitization of profiles associated
with SEA in a single assay, based on proteins in the environment of
the horse. The use of protein extracts was essential because very few
proteins have been assessed in relation to SEA to date. Therefore, in
the early stages of development, we used a range of extracts to maxi-
mize coverage in combination with pure proteins, where available or
where the allergen has been previously associated, thus simulta-
neously maintaining specificity. Furthermore, we observed compara-
ble accuracy between natural extracts and recombinant allergens,
whereas some studies have indicated that the use of the recombinant
component alone may be insufficient for some allergens.37 Although
the eventual goal will be to move toward component-resolved
diagnostics utilizing individual allergen molecules for increased sensi-
tivity and minimizing cross-reactivity, the genus and species must be
identified to enable the production of pure proteins. Component-
resolved diagnostics offers markedly increased accuracy over routine
diagnostic tests (eg, skin prick and specific IgE determination),38 and
enables the accurate selection of allergens to be used for allergen
immunotherapy.39 Moreover, the identification of sensitization to
pure proteins will assist in development of diagnostic tests and treat-
ments. This microarray approach has several advantages. It allows
substantial allergen profiling with minimal sample, collection of less
invasive readily obtained in vivo samples, permits automation, and
enables the generation of mathematical predictive models to assist in
clinical allergy diagnosis.
Protein microarray methods primarily consist of 2 steps: first, the
printing of proteins onto the nitrocellulose slides, and second, the pro-
filing of equine IgE. Printing methods are well established; therefore,
the latter was optimized to enable analysis of SEA BALF and sera sam-
ples. Although it has been suggested that developing technology
means sensitivity is such that many immunoglobulin isotypes in BALF
can be assessed unconcentrated to the nanogram or microgram, it is
often not possible to detect allergen-specific IgE in BALF because of
the low concentration of the isotype present.23,40 Therefore, concen-
tration techniques often must be employed to assess BALF IgE.
Lyophilization41 and centrifugal filtration methods42,43 have been suc-
cessfully utilized to concentrate BALF for immunoglobulin analysis,
but certain techniques, such as ammonium sulfate precipitation, can
result in denaturation of the liable epitopes.44 Similarly, lyophilizing
BALF samples without desalting results in high concentrations of
sodium chloride, which can denature proteins. The most commonly
utilized BALF concentration technique is the centrifugal filter (Amicon
Ultra-15 or Centricon-10) to a 10-fold concentration of
immunoglobulin,42,45-49 but, even this technique results in a 20% loss
of specific IgE and IgG.46
On collection of BALF for immunoglobulin analysis, protease
inhibitors must be added to prevent proteolytic cleavage of proteins,
which would otherwise leave the immunoglobulin unviable. Similarly,
immunoglobulin in BALF is markedly affected by freeze–thaw cycles,
and the inclusion of a cryopreservative in the form of glycerol has
been shown to be effective.50 Therefore, glycerol was added as a
cryoprotectant to a final concentration of 20% to help stabilize the
proteins and prevent formation of ice crystals during freezing that
destroy protein structure. Unfortunately, samples containing
cryopreservative tend to thaw during lyophilization, meaning it was
not possible to achieve a 40-fold concentration using this technique.
To avoid this problem and remove sodium chloride, samples under-
went a buffer exchange using a PD-10 column before lyophilization.
Bronchoalveolar lavage concentrations and techniques were trialed,
varying hybridization temperatures and times were assessed, and
BALF/sera analyzed. The highest binding capacity was observed with
overnight incubation at 4C. When using BALF, the highest binding
was seen using the Amicon filter and the PD-10 elution colu-
mn/lyophilizing at a 40-fold final concentration. The Amicon filter
technique was quicker, easier, decreased the risk of contamination,
TABLE 2 Z-test results with Benjamini-Hochberg corrected
P-values showing all statistically significant allergen between the
severe equine asthma (n = 6) and control group (n = 6; P = .05)
Name
Benjamini-
Hochberg P-value
Dermatophagoides farinae Der f 2 .0004
Blattella germanica Bla g 5 .0004
Aspergillus restrictus Asp r 1 .002
Linum usitatissimum Lin us [pollen] .009
Dermatophagoides pteronyssinus Der p 7 .01
B germanica Bla g 5 .01
Hevea brasiliensis Hev b 11 .01
Triticum polonicum Tri tp .02
H brasiliensis Hev b 5.0101 .02
Penicillium notatum Pen ch .02
Actinidia chinensis Act c 5 .02
Malassezia pachydermatis Mala p .03
Actinidia deliciosa Act d 11 .04
Olea europaea Ole e 2 .04
Anthoxanthum odoratum Ant o [pollen] .04
H brasiliensis Hev b 6.02 .04
Parietaria judaica Par j 1 .04
Alternaria alternata Alt a 1 .04
Triticum turgidum ssp. durum Tri td .05
Aspergillus fumigatus Asp f .05
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and had previously been utilized, and, therefore, this technique was
selected. Interestingly, during optimization, a biased response toward
pollens was observed. Plants are polyploids and show a large number
of gene duplications; hence, high cross-reactivity among species gen-
erally is observed. It is our experience that pollen response in humans
and other animals is commonly amplified.51
Because of the significant correlation of BALF and sera (average
R2 = 0.75), sera were used in subsequent analysis because of the ease
of use. Previous studies comparing the specific IgE profiles of BALF
and sera using ELISA techniques have been limited and contradictory
to date. Previous authors concluded that although BALF may be valu-
able for analysis, sera was of little clinical relevance.21,23 Here, we
demonstrated the ability to profile unconcentrated sera instead of
BALF to assess potential allergens. This approach has several advan-
tages because serum is far easier to collect, store, and prepare for
analysis in comparison to BALF. Collection also is less stressful for the
horse. Moreover, it holds further potential in the use of diagnostic
microarrays because serum is far more stable to ship for analysis.52
Repeatability is an essential factor in the development of new
diagnostic tests. Therefore, the effects of printing lot and mouse anti-
horse IgE 3H10 sources were assessed. These results confirmed
reproducibility among printing lots (average R2 = 0.97). The original
mouse anti-horse IgE 3H10 used was that from a previous study.40
The commercial availability of antibodies is essential in diagnostic
tests; therefore, the 3H10 clone40 was compared with the commer-
cially available BioRad 3H10 (product # MCA5982GA), confirming
reproducibility with the commercially available clone (R2 = 0.90).
Specificity is an important aspect of protein microarrays, which was
confirmed by a protein inhibition assay. In this assay, some cross-
reactivity was seen, predominantly with grass pollens, as well as with
Aspergillus and Penicillium. A previous study reported that pollens from
grasses (Poaceae) often had high immunological cross-reactivity, poten-
tially indicating common antigenic/allergenic component(s).53 Further-
more, cross-reactivity was identified between the genus Penicillium and
Aspergillus, which is expected because taxonomically, the genera Penicil-
lium and Aspergillus have many similarities, because both produce and
contain galactomannans with similar galactofuranosyl and immunogenic
side chains. Cross-reactivity in the fungi group was seen only with
whole protein extracts, emphasizing the importance of including pure
proteins. Analysis of human sera in a variety of assays has indicated that
A fumigatus contains determinants in common with Cladosporium, Can-
dida, Alternaria, Trichophyton, and Epidermophyton,54 but cross-reactivity
was not identified here.
Several allergens of interest identified in our study were consistent
with those previously identified as SEA-associated by ELISA, Western
blot, and RAST methods (A fumigatus, A alternate, E amstelodami, and G
candidum). Ours was the largest panel of proteins tested with a con-
trolled SEA group to date and thus identified new and relevant allergens.
Several SEA-associated allergens identified in our study previously have
been associated with allergic asthma in humans (eg, Dermatophagoides
farina, B germanica, Aspergillus restrictus, Dermatophagoides pteronyssinus).
The novel SEA-associated allergens identified in our study strongly impli-
cate fungi and mite as the main reactants, as well as identifying
previously unrecognized reaction with pollens. This observation confirms
the future potential of specific IgE as a biomarker for the serological
diagnosis of SEA.
Our results have established a reliable protein microarray for
large-scale IgE profiling of environmental proteins of horses, con-
firming identified SEA-associated allergens and elucidating a range of
previously unidentified allergens. The technique is sufficiently sensi-
tive and specific to differentiate between sensitized allergens in SEA
and in control horses. Furthermore, the developed serological assay
enables accurate identification of an individual horse's sensitization
profile. This information provides a reliable, fast, and repeatable
method for screening a wide variety of potential allergens found in
the stable environment in a miniaturized and affordable format, while
offering a platform to support management and treatment of this
debilitating respiratory disorder in horses.
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